These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

937 related articles for article (PubMed ID: 31443516)

  • 41. Identification and targeting of microRNAs modulating acquired chemotherapy resistance in Triple negative breast cancer (TNBC): A better strategy to combat chemoresistance.
    Das S
    Med Hypotheses; 2016 Nov; 96():5-8. PubMed ID: 27959276
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness.
    Shin VY; Chen J; Cheuk IW; Siu MT; Ho CW; Wang X; Jin H; Kwong A
    Cell Death Dis; 2019 Mar; 10(4):270. PubMed ID: 30894512
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
    Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
    Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Omics Analysis of Chemoresistant Triple Negative Breast Cancer Cells Reveals Novel Metabolic Vulnerabilities.
    Kordias D; Kostara CE; Papadaki S; Verigos J; Bairaktari E; Magklara A
    Cells; 2022 Aug; 11(17):. PubMed ID: 36078127
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease.
    Qattan A
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255471
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of INFG/STAT1/NOTCH3 as γ-Mangostin's potential targets for overcoming doxorubicin resistance and reducing cancer-associated fibroblasts in triple-negative breast cancer.
    Lawal B; Wu AT; Chen CH; T A G; Wu SY
    Biomed Pharmacother; 2023 Jul; 163():114800. PubMed ID: 37141739
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dynamic tumor microenvironment, molecular heterogeneity, and distinct immunologic portrait of triple-negative breast cancer: an impact on classification and treatment approaches.
    Nguyen HM; Paulishak W; Oladejo M; Wood L
    Breast Cancer; 2023 Mar; 30(2):167-186. PubMed ID: 36399321
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Increased expression of biological markers as potential therapeutic targets in Saudi women with triple-negative breast cancer.
    Sayed-Ahmed MM; Hafez MM; Al-Shabanah OA; Al-Rejaie SS; Aleisa AM; Al-Yahya AA; Alsheikh A; Al Diab AI; Al-Akeely MH
    Tumori; 2013; 99(4):545-54. PubMed ID: 24326846
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
    Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of retinoic acid receptor α phosphorylation represses the progression of triple-negative breast cancer via transactivating miR-3074-5p to target DHRS3.
    Lou S; Gao H; Hong H; Zhu Z; Zhao H
    J Exp Clin Cancer Res; 2021 Apr; 40(1):141. PubMed ID: 33902658
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Triple-negative breast cancer and the potential for targeted therapy.
    Jhan JR; Andrechek ER
    Pharmacogenomics; 2017 Nov; 18(17):1595-1609. PubMed ID: 29095114
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Paraoxonase-2 is upregulated in triple negative breast cancer and contributes to tumor progression and chemoresistance.
    Campagna R; Pozzi V; Giorgini S; Morichetti D; Goteri G; Sartini D; Serritelli EN; Emanuelli M
    Hum Cell; 2023 May; 36(3):1108-1119. PubMed ID: 36897549
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.
    Nelson ER; Li S; Kennedy M; Payne S; Kilibarda K; Groth J; Bowie M; Parilla-Castellar E; de Ridder G; Marcom PK; Lyes M; Peterson BL; Cook M; Pizzo SV; McDonnell DP; Bachelder RE
    Oncotarget; 2016 Dec; 7(51):84030-84042. PubMed ID: 27768598
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chemotherapy-driven increases in the CDKN1A/PTN/PTPRZ1 axis promote chemoresistance by activating the NF-κB pathway in breast cancer cells.
    Huang P; Ouyang DJ; Chang S; Li MY; Li L; Li QY; Zeng R; Zou QY; Su J; Zhao P; Pei L; Yi WJ
    Cell Commun Signal; 2018 Nov; 16(1):92. PubMed ID: 30497491
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Triple Negative Breast Cancer: A Tale of Two Decades.
    Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
    Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
    [TBL] [Abstract][Full Text] [Related]  

  • 56. RUNX2 prompts triple negative breast cancer drug resistance through TGF-β pathway regulating breast cancer stem cells.
    Lv F; Si W; Xu X; He X; Wang Y; Li Y; Li F
    Neoplasia; 2024 Feb; 48():100967. PubMed ID: 38219710
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Repurposing Drugs as Novel Triple-negative Breast Cancer Therapeutics.
    Das A; Agarwal P; Jain GK; Aggarwal G; Lather V; Pandita D
    Anticancer Agents Med Chem; 2022; 22(3):515-550. PubMed ID: 34674627
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer.
    Deepak KGK; Vempati R; Nagaraju GP; Dasari VR; S N; Rao DN; Malla RR
    Pharmacol Res; 2020 Mar; 153():104683. PubMed ID: 32050092
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeted Therapies for Triple-Negative Breast Cancer.
    Lyons TG
    Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells.
    Panayotopoulou EG; Müller AK; Börries M; Busch H; Hu G; Lev S
    Oncotarget; 2017 Jul; 8(28):45088-45104. PubMed ID: 28187446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.